As a senior communications executive with over twenty-five years of experience in the biopharmaceutical industry, Angela excels in crisp messaging and consistent communications, increasing visibility among key stakeholders, as well as carrying culture and communication throughout the organization. Prior to Twist, she led her own consultancy practice for 20 years, working with biopharmaceutical, medical device and diagnostics clients to create key messages to implement effective communication across external audiences. Prior to starting her own consultancy, Angela headed the investor relations and corporate communications department for Exelixis, Inc. She spent several years at Russell-Welsh, Inc., a boutique healthcare communications agency, working with a variety of public and private clients on a broad range of communications services. She holds a Bachelor of Science degree in cellular and molecular biology and a Bachelor of Arts degree in business marketing, both from the University of Washington. She currently serves on the Board of Directors of the Oregon Bioscience Association.

Mark is experienced in improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. Prior to joining Twist, Mark served as corporate senior vice president, operations, global supply chain at Excelitas Technologies Corporation where he established a global footprint, drove global supply chain optimization measures, enabled scale up and drove revenue growth. His responsibilities included global supply chain planning, global sourcing and procurement supply, internal supply, supply quality and logistics inbound and outbound movement of freight. Prior to Excelitas, Mark was director, global supply chain management and general manager of resale product operations at Bio-Rad, Inc., where he managed buy-sell products, which grew in revenue to $270 million, significantly improving profitability over his time in the role. He previously held leadership positions including vice president operations, global manufacturing, supply chain and logistics at Celerity Group; director, operations management at Solectron corporation; and senior supply chain operations manager at Apple Computer, Inc. Before joining industry, Mark served in the United States Marine Corps. He holds an MBA from National University and a B.S. in electrical and computer engineering from University of Illinois, Urbana-Champaign.

Mike is a seasoned executive with experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses.
Before joining Twist, he co-founded and served as CEO of TeselaGen Biotechnology for a decade, where he spearheaded TeselaGen’s enterprise software platform, providing a comprehensive suite of tools for DNA design, assembly, management and experimental workflows to a range of biotech customers from startups to Fortune 50 companies. Prior to TeselaGen, he was a principal investigator and NIH Career Fellow at Stanford University where he explored the signaling pathways that govern the bacteria cell cycle through the development of an automated epifluorescence microscopy platform including both hardware and software for high-throughput, high-content genetic screens and subsequent data analysis. He also served as director of Stanford Functional Genomics, where he collaborated on the development of the first human and murine genome scale microarrays. Prior to Stanford, Mike served as vice president of software engineering at Neomorphic where he guided development of a laboratory information management system (LIMS) solution for the human

Paula Green is an experienced human resources executive with a track record of developing and delivering high-impact people strategies, solutions, processes and tools that support leadership competencies to empower a high performing organization. Prior to Twist Bioscience, she served as Vice President, Head of Human Resources at QIAGEN, where she oversaw 50 human resources professionals supporting 4,000 employees through mergers and acquisitions, restructurings and other pivotal corporate transactions. She was the human resources manager for Operon Technologies (acquired by QIAGEN) where her responsibilities included creating strategy, overseeing benefits for all employees, and delivering training, recruitment and retention programs. She also worked as a Human Resources Consultant for the Federal Home Loan Bank of San Francisco. Paula holds a BS in Organizational Behavior from the University of San Francisco.

Dr. Chen is a strategic thinker with proven track record of identifying, developing, and commercializing innovative products in NGS, synthetic biology, and other life science areas. He joined Twist shortly after the company was founded and lead product development for both the synthetic biology and NGS product lines. Dr. Chen conceived and implemented a new product line for NGS that includes synthetic controls for SARS-CoV-2 and other infectious diseases, developed gene synthesis and NGS target enrichment biochemistries, workflow, reagent kits, and infrastructure, and built the company’s prototype DNA synthesizer in collaboration with hardware, software, and silicon engineers, which later became a production-scale machine, serving as Twist’s foundation technology. Dr. Chen is the author of numerous peer-reviewed papers and issued patents in the field of oligonucleotide synthesis and application of synthetic oligonucleotides. He earned his Ph.D. in Chemistry from the University of Wisconsin – Madison, and B.Sc. in Chemistry from Peking University in Beijing, China.

Nicole is a visionary sales leader with over 17 years of experience driving commercial success within NGS, synthetic biology, molecular diagnostics and RNA therapeutics. She has a proven track record of building and coaching high-performing sales teams at local, national and global levels, and implementing innovative sales methodologies to meet evolving customer needs. Since joining Twist in 2020, Nicole has consistently delivered high growth sales across various vertical markets, serving in escalating positions within the commercial team. She was appointed SVP of Sales and Support in October 2024. Before Twist Bioscience, Nicole held multiple leadership roles within the North America Custom Solutions & OEM sales teams at QIAGEN. During her tenure at QIAGEN, she successfully led the North American sales teams to achieve more than double team sales in 3 years and was recognized as a QIAGEN President's Circle Award Winner. Previously, Nicole served in senior sales roles at Enzymatics (a QIAGEN company), where she expanded the Western Region by driving customer and revenue growth through new business opportunities. Prior to Enzymatics, Nicole held positions at Affymetrix and USB Corporation where she substantially increased revenue growth through strategic account management and business development. Nicole holds a B.S. in Biochemistry from Colorado State University.

Adam has deep financial acumen and strategic planning expertise across diverse businesses along with a track record of collaborating across teams to drive profitable growth. Prior to joining Twist, Adam served as chief financial officer of Eargo, Inc., where he was responsible for finance, accounting, investor relations, business operations, internal audit and information technology. During his tenure at Eargo, revenue increased more than 300% over the course of two years. Prior to Eargo, Adam was vice president, worldwide financial planning and analysis and business operations at Tesla, Inc. where he was responsible for worldwide pricing, forecasting, capital planning, development of internal controls, and optimization of business operations. Previously, Adam served as vice president, finance and chief financial officer, cardiovascular care at Cardinal Health as the finance leader for the worldwide Cordis Cardiovascular business. He held a series of roles of increasing responsibility at Johnson & Johnson, where he led the divestiture of Cordis to Cardinal Health. He held additional positions within Johnson & Johnson including controller of the diabetes franchise, manager of supply chain and quality finance and customer service finance. Adam holds an MBA from the University of Southern California, Marshall School of Business and a B.S. in chemical engineering from the University of California at Berkeley.

Jimmy is a strategic marketing leader with more than 25 years of experience delivering business growth through product innovation, expanding global customer bases and market development across the genomics, molecular biology, and clinical diagnostics sectors. Since joining Twist in 2021, Jimmy has built a high-performing marketing and product organization, led the commercialization of numerous products and delivered industry-leading growth across Twist's product portfolio in alignment with evolving customer and market dynamics, including the rapid expansion of Twist’s NGS offering from target enrichment into a broad NGS wet-lab portfolio. He was appointed SVP of product and marketing in December 2025.

Prior to Twist Bioscience, Jimmy held various senior product and commercial leadership roles at Agilent Technologies, most recently serving as Associate Vice President and Head of Genomics Marketing. Previously, he held escalating positions in research and development, tech transfer, lab operations, and program leadership at Aclara Biosciences and Monogram Biosciences (now Labcorp). Jimmy holds an MBA from the University of California, Berkeley, Haas School of Business, an M.S. in Biological Chemistry from UC Davis, and a B.S. in Bioscience and Technology from Tsinghua University.

Patrick has a strong track record of high-growth sales in bioreagent, B2B and custom manufacturing organizations. His technical background paired with his ability to identify customer's unmet needs make him the ideal fit to lead our commercial organization. Before Twist Bioscience, Paddy served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. Prior to Enzymatics, Paddy held positions with increasing commercial focus, including Director of Business Development at Agilent Technologies, Director of Product Development for Beckman Coulter Molecular Diagnostics, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. In addition, Paddy currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.

As an early pioneer in the high-throughput synthesis and sequencing of DNA, Dr. Leproust is disrupting markets to enable the exponential growth of DNA-based applications including chemicals/materials, diagnostics, therapeutics, food and digital data storage. In 2020, BIO presented her with the Rosalind Franklin Award for Leadership. Foreign Policy named her one of their 100 Leading Global Thinkers and Fast Company named her one of the Most Creative People in Business. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team. Dr. Leproust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. She serves on the board of directors of GeneDx and Atlas Data Storage as well as the Nuclear Threat Initiative, a Washington DC-based nonprofit, nonpartisan global security organization focused on reducing biological threats. She is an investment advisor for NFX Bio and co-founder of